Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • Breakthrough Discoveries
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Steven Chmura Image

      Steven J. Chmura, M.D., Ph.D.

      Department of Breast Radiation Oncology, Division of Radiation Oncology

      About Dr. Steven Chmura

      Dr. Steven J. Chmura is Professor and Chair of the Department of Breast Radiation Oncology at MD Anderson Cancer Center. He is nationally recognized for his leadership in clinical trials and research focused on oligometastatic cancer, advancing novel radiation therapies to improve patient outcomes and quality of life.

      Dr. Chmura co-leads national trials and translational research programs that integrate cutting-edge radiation oncology with systemic therapies. His work aims to optimize treatment for patients with limited metastatic disease, emphasizing both survival and quality of life.

      With a strong commitment to patient-centered care, Dr. Chmura’s research also explores the impact of cancer treatment on patients’ well-being and daily functioning. He has published extensively on these topics and is a leader in shaping future standards of care in radiation oncology.

      Dr. Chmura completed his medical training and PhD at the University of Chicago and has held academic appointments there before joining MD Anderson in 2026.


      Read More

      Present Title & Affiliation

      Primary Appointment

      Professor and Chairman, Department of Breast Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Education & Training

      Degree-Granting Education

      1997University of Chicago Department of Pathology, Ph.D
      1999University of Chicago Pritzker School of Medicine, M.D
      1992University of Illinois, Urbana, Illinois, US, Biology and Psychology, B.S

      Postgraduate Training

      2000-2004Residency, University of Chicago Hospital, University of Chicago School of Medicine
      1999-2000Internship, Weiss/University of Chicago Program B, Weiss Hospital

      Licenses & Certifications

      2026Texas Medical License
      2004Illinois Medical License (IDPR)

      Experience & Service

      Faculty Academic Appointments

      Professor, Department of Neurosurgery, University of Chicago, Chicago, Illinois, 2023 - 2026

      Professor, Department of Medicine, Hematology/Oncology, University of Chicago, Chicago, Illinois, 2021 - 2026

      Professor, Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois, 2020 - 2026

      Associate Professor, Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois, 2012 - 2020

      Assistant Professor, Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois, 2006 - 2012

      Instructor, Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois, 2004 - 2006

      Administrative Appointments/Responsibilities

      Scientific Director, Cancer Clinical Trials Office, University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, 2019 - 2022

      Director of Clinical and Translational Research, Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois, 2008 - 2026

      Member, University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, 2004 - 2026

      Other Professional Positions

      Member, Clinical Research Advisory Committee (CRAC), 2016 - 2019

      Vice Chairman, SAM (Safety and Monitoring) Committee for Clinical Trials, University of Chicago), 2010 - 2019

      Program Director for Radiation Oncology Residency Training (GME), University of Chicago, Chicago, Illinois, 2010 - 2018

      Co-Director, University of Chicago Breast Cancer Spore Program #5, 2009 - 2010

      Member, RADRAC (Radioisotopes & Radioactive Drug Research Advisory Committee), 2009 - 2019

      Intramural Institutional Committee Activities

      Member, Clinical Research Advisory Committee (CRAC), University of Chicago, 2016 - 2019

      Vice Chairman, Safety and Monitoring Committee for Clinical Trials, University of Chicago, 2010 - 2019

      Co-director, University of Chicago Breast Cancer Spore Program #5, University of Chicago, 2009 - 2010

      Extramural Institutional Committee Activities

      Member, Committee on Academic Promotion (CAP), Pritzker School of Medicine, 2019 - 2026

      Member, Radioisotopes & Radioactive Drug Research Advisory Committee (RADRAC), University of Chicago, 2009 - 2019

      Honors & Awards

      2026University of Chicago Comprehensive Cancer Center Excellence in Leadership award
      2022 - 2024ARRO Teacher of the year award
      2016Samuel Hellman Teacher of the Year award
      2012 - 2014Association of Residents in Radiation Oncology: Residence Teaching Award
      2011University of Chicago Faculty Role Model Nomination
      2008ARRO (American Association Radiation Oncology Residents) Teacher of the Year Award
      2007ARRO Teacher of the Year Award
      2006ARRO Teacher of the Year Award
      2005Cancer Research Foundation New Faculty award
      2005ASTRO 2005 Young Scientist Award
      2004ASTRO 2004 Outstanding Abstract Award (Top 1%)
      1999Basic science research award for outstanding work in Radiation Oncology
      1998Clinical Pathophysiology selected instructor for the Pritzker School of Medicine
      1996Clinical Pathology selected instructor for the Pritzker School of Medicine
      1994NIH Training grant in Growth and Development, University of Chicago
      1992University Honors, University of Illinois Champaign Urbana
      1992Summa cum laude, University of Illinois Champaign Urbana
      1992Phi Beta Kappa, University of Illinois Champaign Urbana

      Selected Publications

      Peer-Reviewed Articles

      1. Leng JX, Arshad M, Carpenter DJ, Qazi J, Huang C, Serra L, Vaios E, Reitman ZJ, Floyd SR, Kirkpatrick JP, Fecci PE, Chmura SJ, Hong JC, Sperduto PW, Salama JK, Mullikin TC. Impact of Radionecrosis and Local Recurrence on Overall Survival After Stereotactic Radiosurgery for Brain Metastases. Adv Radiat Oncol 11(11):102098, 2026. e-Pub 2026. PMID: 42388439.
      2. Ji F, Zheng L, Chen D, Xia P, Zou Z, Liu W, Bugno J, Naccasha EZ, Piffko A, Wen C, Li K, Xu L, Luo SZ, Huang X, Wang J, Ju C, Liu B, Ji Y, Li H, Chmura SJ, Pitroda SP, Liang HL, He C, Weichselbaum RR. Myeloid reprogramming generates myeloid-derived activating cells to potentiate radiotherapy and suppress metastasis. Cancer Cell 44(10):2011-2028.e7, 2026. e-Pub 2026. PMID: 42753736.
      3. Morse M, Zartarian M, Savage B, O'Connor P, Nicholas D, Jones H, Gil C, Wroblewski D, Chmura S, Biswas N, Bocketti C, Willard G, Blumerman S, Hattenrath T, Gowie D, Mingle L, Lauper U. Legionnaires Disease Associated with a Private-Use Hot Tub in a Vacation Rental Property - New York, October 2024-April 2025. MMWR Morb Mortal Wkly Rep 75(22):274-279, 2026. e-Pub 2026. PMID: 42275248.
      4. Chen D, Wang L, Wen C, Piffko A, Bugno J, Yu X, Wang P, Ji F, Naccasha EZ, Wang J, Huang X, Chmura SJ, Pitroda SP, He C, Liang HL, Weichselbaum RR. Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function. J Exp Med 223(1), 2026. e-Pub 2026. PMID: 41196643.
      5. Cooper BT, Iams WT, Page DB, Yuan Y, Gerber NK, Luke JJ, Gibbs JP, Gregory RC, Wong KK, Deng J, Perera SA, Ding K, Roberts ER, Berger A, Christensen CL, Tong EX, Maldonado Lopez AE, Appleman VA, Leonard EJ, Parent A, Huang YC, Bay C, Li C, Lineberry N, Raizer J, Olson DJ, Chmura SJ. Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors. Cancer Res Commun 5(12):2249-2263, 2025. e-Pub 2025. PMID: 41296842.
      6. Huang CC, Carpenter DJ, Leng J, Qazi J, Natarajan B, Arshad M, Moravan MJ, Vaios EJ, Reitman ZJ, Kirkpatrick JP, Floyd SR, Chmura SJ, Hong JC, Salama JK, Mullikin TC. Clinical Parameters Associated With Intracranial Progression Burden Following an Initial Stereotactic Radiosurgery Course in a Multi-institutional Brain Metastases Cohort. Adv Radiat Oncol 10(9):101859, 2025. e-Pub 2025. PMID: 40800218.
      7. Qazi JJ, Carpenter DJ, Leng J, Huang CC, Chmura SJ, Arshad M, Reitman ZJ, Kirkpatrick JP, Hong JC, Floyd SR, Mullikin TC, Salama JK. Multi-institutional Outcomes after Stereotactic Radiosurgery for Gastrointestinal Brain Metastases. Adv Radiat Oncol 10(7):101795, 2025. e-Pub 2025. PMID: 40538502.
      8. Piffko A, Yang K, Panda A, Heide J, Tesak K, Wen C, Zawieracz K, Wang L, Naccasha EZ, Bugno J, Fu Y, Chen D, Donle L, Lengyel E, Tilley DG, Mack M, Rock RS, Chmura SJ, Vokes EE, He C, Pitroda SP, Liang HL, Weichselbaum RR. Radiation-induced amphiregulin drives tumour metastasis. Nature 643(8072):810-819, 2025. e-Pub 2025. PMID: 40369065.
      9. Qazi JJ, Van Swearingen AED, Carpenter DJ, Broadwater G, Leng JX, Arshad M, Chmura SJ, Bansal R, Alder L, Fecci PE, Kirkpatrick JP, Salama JK, Mullikin TC, Floyd SR, Anders CK. Impact of systemic therapy after stereotactic radiosurgery in patients with limited brain-only metastasis. Neurooncol Adv 7(1):vdaf214, 2025. e-Pub 2025. PMID: 41497447.
      10. Ye A, Mack M, Ursu S, Chmura S, Steiner R, Heath T, Handumrongkul C, Debs R. One IV HEDGES DNA vector administration encoding hGLA or hGH produces durable hGLA and hGH serum lvels in immunocompetent mice. PLoS One 20(10):e0318977, 2025. e-Pub 2025. PMID: 41171941.
      11. Wen C, Wang L, Piffko A, Chen D, Yu X, Zawieracz K, Bugno J, Yang K, Naccasha EZ, Ji F, Wang J, Huang X, Luo SY, Tan L, Shen B, Luo C, McNerney ME, Chmura SJ, Arina A, Pitroda S, He C, Liang HL, Weichselbaum RR. YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production. J Clin Invest 134(23), 2024. e-Pub 2024. PMID: 39325547.
      12. Bestvina CM, Hara JHL, Karrison T, Bowar B, Chin J, Garassino MC, Pitroda SP, Thawani R, Vokes EE, Gan G, Zhang J, Baschnagel AM, Campbell TC, Chmura S, Juloori A. DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer 25(8):e448-e452, 2024. e-Pub 2024. PMID: 39242330.
      13. Lynch C, Korpics MC, Katipally RR, Bestvina CM, Pitroda SP, Patel JD, Luke JJ, Chmura SJ, Juloori A. Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials. Eur J Cancer 209:114264, 2024. e-Pub 2024. PMID: 39106643.
      14. Leng JX, Carpenter DJ, Huang C, Qazi J, Arshad M, Mullikin TC, Reitman ZJ, Kirkpatrick JP, Floyd SR, Fecci PE, Chmura SJ, Hong JC, Salama JK. Determinants of Symptomatic Intracranial Progression After an Initial Stereotactic Radiosurgery Course. Adv Radiat Oncol 9(6):101475, 2024. e-Pub 2024. PMID: 38690297.
      15. Hou Y, Yang K, Wang L, Wang J, Huang X, Piffko A, Luo SZ, Yu X, Rao E, Martinez C, Bugno J, Mack M, Vokes EE, Pitroda SP, Chmura SJ, Weichselbaum RR, Liang HL. Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites. Clin Cancer Res 30(9):1945-1958, 2024. e-Pub 2024. PMID: 38427437.
      16. Lynch C, Korpics MC, Katipally RR, Wu T, Bestvina CM, Pitroda S, Chmura SJ, Juloori A. Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials. Int J Radiat Oncol Biol Phys 118(5):1519-1530, 2024. e-Pub 2024. PMID: 38199382.
      17. Perez B, Aljumaily R, Marron TU, Shafique MR, Burris H, Iams WT, Chmura SJ, Luke JJ, Edenfield W, Sohal D, Liao X, Boesler C, Machl A, Seebeck J, Becker A, Guenther B, Rodriguez-Gutierrez A, Antonia SJ. Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors. ESMO Open 9(2):102217, 2024. e-Pub 2024. PMID: 38320431.
      18. Driscoll RK, Lyne SB, Voce DJ, Maraka S, Gondi V, Chmura SJ, Dixit KS, Kumthekar PU, Karrison TG, Pytel P, Collins JM, Stupp R, Merrell RT, Lukas RV, Yamini B. A multi-institutional phase I study of acetazolamide with temozolomide in adults with newly diagnosed MGMT-methylated malignant glioma. Neurooncol Adv 6(1):vdae014, 2024. e-Pub 2024. PMID: 38420615.
      19. Wang L, Si W, Yu X, Piffko A, Dou X, Ding X, Bugno J, Yang K, Wen C, Zhang L, Chen D, Huang X, Wang J, Arina A, Pitroda S, Chmura SJ, He C, Liang HL, Weichselbaum R. Epitranscriptional regulation of TGF-beta pseudoreceptor BAMBI by m6A/YTHDF2 drives extrinsic radioresistance. J Clin Invest 133(24), 2023. e-Pub 2023. PMID: 38099498.
      20. Pusztai L, Rozenblit M, Dubsky P, Bachelot T, Kirby AM, Linderholm BK, White JR, Chmura SJ, Carey LA, Chua BH, Miller KD. De Novo Oligometastatic Breast Cancer. J Clin Oncol 41(34):5237-5241, 2023. e-Pub 2023. PMID: 37607325.
      21. Karapetyan L, Iheagwara UK, Olson AC, Chmura SJ, Skinner HK, Luke JJ. Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations. J Natl Cancer Inst 115(11):1278-1293, 2023. e-Pub 2023. PMID: 37348864.
      22. Wang L, Dou X, Chen S, Yu X, Huang X, Zhang L, Chen Y, Wang J, Yang K, Bugno J, Pitroda S, Ding X, Piffko A, Si W, Chen C, Jiang H, Zhou B, Chmura SJ, Luo C, Liang HL, He C, Weichselbaum RR. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell 41(7):1294-1308.e8, 2023. e-Pub 2023. PMID: 37236197.
      23. Milano MT, Salama JK, Chmura SJ. Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy?. J Natl Cancer Inst 115(6):605-607, 2023. e-Pub 2023. PMID: 35094086.
      24. Korpics MC, Onderdonk BE, Dadey RE, Hara JH, Karapetyan L, Zha Y, Karrison TG, Olson AC, Fleming GF, Weichselbaum RR, Bao R, Chmura SJ, Luke JJ. Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest 133(10), 2023. e-Pub 2023. PMID: 37183819.
      25. Carpenter DJ, Leng J, Arshad M, Giles W, Kirkpatrick JP, Floyd SR, Chmura SJ, Salama JK, Hong JC. Intracranial and Extracranial Progression and Their Correlation With Overall Survival After Stereotactic Radiosurgery in a Multi-institutional Cohort With Brain Metastases. JAMA Netw Open 6(4):e2310117, 2023. e-Pub 2023. PMID: 37099292.
      26. Spurr LF, Martinez CA, Kang W, Chen M, Zha Y, Hseu R, Gutiontov SI, Turchan WT, Lynch CM, Pointer KB, Chang P, Murgu S, Husain AN, Cody B, Vokes EE, Bestvina CM, Patel JD, Diehn M, Gajewski TF, Weichselbaum RR, Chmura SJ, Pitroda SP. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer 3(12):1498-1512, 2022. e-Pub 2022. PMID: 36443406.
      27. Lukas RV, Chmura SJ, Parney IF, Mammoser A, Smith SM, Li J. Neuro-oncology at the American Society for Clinical Oncology 2022 Annual Meeting. Neurooncol Pract 9(6):552-558, 2022. e-Pub 2022. PMID: 36388417.
      28. Vaishnavi A, Juan J, Jacob M, Stehn C, Gardner EE, Scherzer MT, Schuman S, Van Veen JE, Murphy B, Hackett CS, Dupuy AJ, Chmura SA, van der Weyden L, Newberg JY, Liu A, Mann K, Rust AG, Weiss WA, Kinsey CG, Adams DJ, Grossmann A, Mann MB, McMahon M. Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis. Cancer Res 82(22):4261-4273, 2022. e-Pub 2022. PMID: 36112789.
      29. Korpics MC, Katipally RR, Partouche J, Cutright D, Pointer KB, Bestvina CM, Luke JJ, Pitroda SP, Dignam JJ, Chmura SJ, Juloori A. Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys 114(4):645-654, 2022. e-Pub 2022. PMID: 35753553.
      30. Carpenter DJ, Natarajan B, Arshad M, Natesan D, Schultz O, Moravan MJ, Read C, Lafata KJ, Giles W, Fecci P, Mullikin TC, Reitman ZJ, Kirkpatrick JP, Floyd SR, Chmura SJ, Hong JC, Salama JK. Prognostic Model for Intracranial Progression after Stereotactic Radiosurgery: A Multicenter Validation Study. Cancers (Basel) 14(21), 2022. e-Pub 2022. PMID: 36358606.
      31. Bestvina CM, Pointer KB, Karrison T, Al-Hallaq H, Hoffman PC, Jelinek MJ, Juloori A, Melotek JM, Murgu S, Partouche J, Vokes EE, Weichselbaum RR, Pitroda SP, Patel JD, Chmura SJ. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol 17(1):130-140, 2022. e-Pub 2022. PMID: 34500113.
      32. Xiao A, Luke JJ, Partouche J, Karrison T, Chmura SJ, Al-Hallaq HA. Evaluation of Dose Distribution to Organs-at-Risk in a Prospective Phase 1 Trial of Pembrolizumab and Multisite Stereotactic Body Radiation Therapy (SBRT). Pract Radiat Oncol 12(1):68-77, 2022. e-Pub 2022. PMID: 34607037.
      33. Pathmarajah T, Katipally RR, Flores-Martinez E, Farrey KJ, Korpics MC, Sivananthan AP, Warnke PC, Chmura SJ, Yenice KM, Pitroda SP. Linear accelerator-based stereotactic radiosurgery for glossopharyngeal neuralgia is safe and effective - Report of two cases. J Radiosurg SBRT 8(2):151-153, 2022. e-Pub 2022. PMID: 36275126.
      34. Dixit KS, Sachdev S, Amidei C, Kumthekar P, Kruser TJ, Gondi V, Grimm S, Lukas RV, Nicholas MK, Chmura SJ, Fought AJ, Mehta M, Raizer JJ. A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas. J Neurooncol 155(3):297-306, 2021. e-Pub 2021. PMID: 34689306.
      35. Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res 27(20):5510-5518, 2021. e-Pub 2021. PMID: 34168049.
      36. Gutiontov SI, Turchan WT, Spurr LF, Rouhani SJ, Chervin CS, Steinhardt G, Lager AM, Wanjari P, Malik R, Connell PP, Chmura SJ, Juloori A, Hoffman PC, Ferguson MK, Donington JS, Patel JD, Vokes EE, Weichselbaum RR, Bestvina CM, Segal JP, Pitroda SP. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep 11(1):20059, 2021. e-Pub 2021. PMID: 34625620.
      37. Dai J, Zha Y, Foster CC, Luke JJ, Chmura SJ, Hoffman MD. Punctate Anetoderma After Colony-Stimulating Factor 1 Receptor and Programmed Cell Death 1 Blockade With Irradiation: Clinicopathologic Characterization of a Novel Eruption. JAMA Dermatol 157(8):998-1000, 2021. e-Pub 2021. PMID: 34190956.
      38. Chmura S, Winter KA, Robinson C, Pisansky TM, Borges V, Al-Hallaq H, Matuszak M, Park SS, Yi S, Hasan Y, Bazan J, Wong P, Yoon HA, Horton J, Gan G, Milano MT, Sigurdson ER, Moughan J, Salama JK, White J. Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. JAMA Oncol 7(6):845-852, 2021. e-Pub 2021. PMID: 33885704.
      39. Yang K, Hou Y, Zhang Y, Liang H, Sharma A, Zheng W, Wang L, Torres R, Tatebe K, Chmura SJ, Pitroda SP, Gilbert JA, Fu YX, Weichselbaum RR. Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J Exp Med 218(3), 2021. e-Pub 2021. PMID: 33496784.
      40. Rokni MB, Pointer KB, George J, Luke JJ, Chmura SJ, Redler G. Radiation treatment planning study to investigate feasibility of delivering Immunotherapy in Combination with Ablative Radiosurgery to Ultra-High DoSes (ICARUS). J Appl Clin Med Phys 22(3):196-206, 2021. e-Pub 2021. PMID: 33626240.
      41. Hou Y, Liang HL, Yu X, Liu Z, Cao X, Rao E, Huang X, Wang L, Li L, Bugno J, Fu Y, Chmura SJ, Wu W, Luo SZ, Zheng W, Arina A, Jutzy J, McCall AR, Vokes EE, Pitroda SP, Fu YX, Weichselbaum RR. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med 13(582), 2021. e-Pub 2021. PMID: 33627484.
      42. Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez C, Janisch LA, Hseu RD, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res 26(24):6437-6444, 2020. e-Pub 2020. PMID: 33028595.
      43. Xiao A, Jutzy J, Hubert G, Edens M, Washington M, Hasan Y, Chmura SJ, Al-Hallaq HA. A study of the dosimetric impact of daily setup variations measured with cone-beam CT on three-dimensional conformal radiotherapy for early-stage breast cancer delivered in the prone position. J Appl Clin Med Phys 21(12):146-154, 2020. e-Pub 2020. PMID: 33124774.
      44. Korpics MC, Polley MY, Bhave SR, Redler G, Pitroda SP, Luke JJ, Chmura SJ. A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab. Int J Radiat Oncol Biol Phys 108(1):189-195, 2020. e-Pub 2020. PMID: 32569799.
      45. Samson P, Ning MS, Shaverdian N, Shepherd AF, Gomez DR, McGinnis GJ, Nitsch PL, Chmura S, O'Reilly MS, Lee P, Chang JY, Robinson C, Lin SH. Clinical and Radiographic Presentations of COVID-19 Among Patients Receiving Radiation Therapy for Thoracic Malignancies. Adv Radiat Oncol 5(4):700-704, 2020. e-Pub 2020. PMID: 32395673.
      46. Chen C, Liao Z, Chmura SJ, Weichselbaum RR. Coronavirus Disease 2019 Infection Prevention and Control Practices in Wuhan Radiation Therapy. Adv Radiat Oncol 5(4):637-639, 2020. e-Pub 2020. PMID: 32775773.
      47. Kumar S, Chmura S, Robinson C, Lin SH, Gadgeel SM, Donington J, Feliciano J, Stinchcombe TE, Werner-Wasik M, Edelman MJ, Moghanaki D. Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic. J Thorac Oncol 15(7):1137-1146, 2020. e-Pub 2020. PMID: 32360578.
      48. Lee EQ, Zhang P, Wen PY, Gerstner ER, Reardon DA, Aldape KD, deGroot JF, Pan E, Raizer JJ, Kim LJ, Chmura SJ, Robins HI, Connelly JM, Battiste JD, Villano JL, Wagle N, Merrell RT, Wendland MM, Mehta MP. NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer 126(12):2821-2828, 2020. e-Pub 2020. PMID: 32154928.
      49. Abbott TR, Dhamdhere G, Liu Y, Lin X, Goudy L, Zeng L, Chemparathy A, Chmura S, Heaton NS, Debs R, Pande T, Endy D, La Russa MF, Lewis DB, Qi LS. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza. Cell 181(4):865-876.e12, 2020. e-Pub 2020. PMID: 32353252.
      50. Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, Bovi JA, Robinson C, Konski A, Khuntia D, Grosshans D, Benzinger TLS, Bruner D, Gilbert MR, Roberge D, Kundapur V, Devisetty K, Shah S, Usuki K, Anderson BM, Stea B, Yoon H, Li J, Laack NN, Kruser TJ, Chmura SJ, Shi W, Deshmukh S, Mehta MP, Kachnic LA. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol 38(10):1019-1029, 2020. e-Pub 2020. PMID: 32058845.
      51. Tatebe K, Chmura SJ, Connell PP. Elevated Radiation Therapy Toxicity in the Setting of Germline PTEN Mutation. Pract Radiat Oncol 9(6):492-495, 2019. e-Pub 2019. PMID: 31185301.
      52. Handumrongkul C, Ye AL, Chmura SA, Soroceanu L, Mack M, Ice RJ, Thistle R, Myers M, Ursu SJ, Liu Y, Kashani-Sabet M, Heath TD, Liggitt D, Lewis DB, Debs R. Durable multitransgene expression in vivo using systemic, nonviral DNA delivery. Sci Adv 5(11):eaax0217, 2019. e-Pub 2019. PMID: 31807699.
      53. Arina A, Beckett M, Fernandez C, Zheng W, Pitroda S, Chmura SJ, Luke JJ, Forde M, Hou Y, Burnette B, Mauceri H, Lowy I, Sims T, Khodarev N, Fu YX, Weichselbaum RR. Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat Commun 10(1):3959, 2019. e-Pub 2019. PMID: 31477729.
      54. Ni L, Chmura SJ, Golden DW. National Radiation Oncology Medical Student Clerkship Trends From 2013 to 2018. Int J Radiat Oncol Biol Phys 104(1):24-26, 2019. e-Pub 2019. PMID: 30605753.
      55. Bloom BC, Augustyn A, Pezzi TA, Menon H, Mayo LL, Shah SJ, Schwartz DL, Chmura SJ, Johnson FM, Welsh JW, Chun SG. Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab. Front Oncol 9:223, 2019. e-Pub 2019. PMID: 31024834.
      56. Natarajan BD, Rushing CN, Cummings MA, Jutzy JM, Choudhury KR, Moravan MJ, Fecci PE, Adamson J, Chmura SJ, Milano MT, Kirkpatrick JP, Salama JK. Predicting intracranial progression following stereotactic radiosurgery for brain metastases: Implications for post SRS imaging. J Radiosurg SBRT 6(3):179-187, 2019. e-Pub 2019. PMID: 31998538.
      57. Rydzewski NR, Khan AJ, Strauss JB, Chmura SJ. Mortality After Stereotactic Radiosurgery for Brain Metastases and Implications for Optimal Utilization: A National Cancer Database Study. Am J Clin Oncol 41(11):1142-1147, 2018. e-Pub 2018. PMID: 29642077.
      58. McKillip RP, Kauffmann G, Chmura SJ, Golden DW. Structured Radiation Oncology Clerkship Curricula: Evaluating the Effect on Residency Applicant Knowledge of Radiation Oncology. J Am Coll Radiol 15(9):1330-1334, 2018. e-Pub 2018. PMID: 30017622.
      59. Hussain F, Horbinski CM, Chmura SJ, Yamini B, Lukas RV. Response to BRAF/MEK Inhibition After Progression With BRAF Inhibition in a Patient With Anaplastic Pleomorphic Xanthoastrocytoma. Neurologist 23(5):163-166, 2018. e-Pub 2018. PMID: 30169370.
      60. Patel JD, Chmura SJ. Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer?. Cancer 124(14):2878-2880, 2018. e-Pub 2018. PMID: 29906817.
      61. Xiao A, Crosby J, Malin M, Kang H, Washington M, Hasan Y, Chmura SJ, Al-Hallaq HA. Single-institution report of setup margins of voluntary deep-inspiration breath-hold (DIBH) whole breast radiotherapy implemented with real-time surface imaging. J Appl Clin Med Phys 19(4):205-213, 2018. e-Pub 2018. PMID: 29935001.
      62. Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol 36(16):1611-1618, 2018. e-Pub 2018. PMID: 29437535.
      63. Akthar AS, Hellekson CD, Ganai S, Hahn OM, Maggiore RJ, Cohen EE, Posner MC, Chmura SJ, Howard AR, Golden DW. Interdisciplinary Oncology Education: a National Survey of Trainees and Program Directors in the United States. J Cancer Educ 33(3):622-626, 2018. e-Pub 2018. PMID: 27873183.
      64. Chmura SJ, Connell PP, Weichselbaum RR. Retuning the Radio in Radiobiology. J Natl Cancer Inst 110(4):325-326, 2018. e-Pub 2018. PMID: 29126281.
      65. Choi DH, Chmura SA, Ramachandran V, Dionis-Petersen KY, Kobayashi Y, Nishi T, Luikart H, Dimbil S, Kobashigawa J, Khush K, Lewis DB, Fearon WF. The ratio of circulating regulatory cluster of differentiation 4 T cells to endothelial progenitor cells predicts clinically significant acute rejection after heart transplantation. J Heart Lung Transplant 37(4):496-502, 2018. e-Pub 2018. PMID: 29198869.
      66. Hong JC, Ayala-Peacock DN, Lee J, Blackstock AW, Okunieff P, Sung MW, Weichselbaum RR, Kao J, Urbanic JJ, Milano MT, Chmura SJ, Salama JK. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. PLoS One 13(4):e0195149, 2018. e-Pub 2018. PMID: 29649281.
      67. Kauffmann G, Buerki RA, Lukas RV, Gondi V, Chmura SJ. Case Report of Bone Marrow-Sparing Proton Therapy Craniospinal Irradiation for Central Nervous System Myelomatosis. Cureus 9(11):e1885, 2017. e-Pub 2017. PMID: 29387514.
      68. Belcher AH, Liu X, Chmura S, Yenice K, Wiersma RD. Towards frameless maskless SRS through real-time 6DoF robotic motion compensation. Phys Med Biol 62(23):9054-9066, 2017. e-Pub 2017. PMID: 29131807.
      69. Chmura SJ, Weichselbaum RR. Rhythmic radiotherapy beats down TGF-beta. Cell Cycle 16(15):1391, 2017. e-Pub 2017. PMID: 28723240.
      70. Wong AC, Chmura SJ. PMRT: Please Mind Randomized Trials. Int J Radiat Oncol Biol Phys 98(5):976-977, 2017. e-Pub 2017. PMID: 28721908.
      71. Lewis SL, Porceddu S, Nakamura N, Palma DA, Lo SS, Hoskin P, Moghanaki D, Chmura SJ, Salama JK. Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of >1000 Radiation Oncologists. Am J Clin Oncol 40(4):418-422, 2017. e-Pub 2017. PMID: 25647831.
      72. Fearon WF, Okada K, Kobashigawa JA, Kobayashi Y, Luikart H, Sana S, Daun T, Chmura SA, Sinha S, Cohen G, Honda Y, Pham M, Lewis DB, Bernstein D, Yeung AC, Valantine HA, Khush K. Angiotensin-Converting Enzyme Inhibition Early After Heart Transplantation. J Am Coll Cardiol 69(23):2832-2841, 2017. e-Pub 2017. PMID: 28595700.
      73. Das LC, Golden DW, Perevalova E, Wong AC, De Nardo K, Stepaniak C, Joyce DS, McCabe BP, Hasan Y, Chmura SJ, McCall A. A feasibility study of 2-mm bolus for postmastectomy radiation therapy. Pract Radiat Oncol 7(3):161-166, 2017. e-Pub 2017. PMID: 28089526.
      74. Hasan Y, Waller J, Yao K, Chmura SJ, Huo D. Utilization trend and regimens of hypofractionated whole breast radiation therapy in the United States. Breast Cancer Res Treat 162(2):317-328, 2017. e-Pub 2017. PMID: 28120272.
      75. Melotek JM, Chmura SJ. Oligometastasis-Directed Ablative Therapy: A Clinical Trial Question. Int J Radiat Oncol Biol Phys 97(3):448, 2017. e-Pub 2017. PMID: 28126295.
      76. Smith GL, Ganz PA, Bekelman JE, Chmura SJ, Dignam JJ, Efstathiou JA, Jagsi R, Johnstone PA, Steinberg ML, Williams SB, Yu JB, Zietman AL, Weichselbaum RR, Tina Shih YC. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. Int J Radiat Oncol Biol Phys 97(3):450-461, 2017. e-Pub 2017. PMID: 28011046.
      77. Al-Hallaq HA, Chmura SJ, Salama JK, Lowenstein JR, McNulty S, Galvin JM, Followill DS, Robinson CG, Pisansky TM, Winter KA, White JR, Xiao Y, Matuszak MM. Benchmark Credentialing Results for NRG-BR001: The First National Cancer Institute-Sponsored Trial of Stereotactic Body Radiation Therapy for Multiple Metastases. Int J Radiat Oncol Biol Phys 97(1):155-163, 2017. e-Pub 2017. PMID: 27843033.
      78. Oskvarek JJ, Brower JV, Mohindra P, Raleigh DR, Chmura SJ, Golden DW. Educational Impact of a Structured Radiation Oncology Clerkship Curriculum: An Interinstitutional Comparison. J Am Coll Radiol 14(1):96-102, 2017. e-Pub 2017. PMID: 27652570.
      79. Al-Hallaq HA, Chmura S, Salama JK, Winter KA, Robinson CG, Pisansky TM, Borges V, Lowenstein JR, McNulty S, Galvin JM, Followill DS, Timmerman RD, White JR, Xiao Y, Matuszak MM. Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. Pract Radiat Oncol 6(6):e291-e298, 2016. e-Pub 2016. PMID: 27345129.
      80. Wong AC, Watson SP, Pitroda SP, Son CH, Das LC, Stack ME, Uppal A, Oshima G, Khodarev NN, Salama JK, Weichselbaum RR, Chmura SJ. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer 122(14):2242-50, 2016. e-Pub 2016. PMID: 27206146.
      81. Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM, Mohile N, Kee AY, Colman H, Cavaliere R, Kesari S, Chmura SJ, Mehta M. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. J Neurooncol 126(2):309-16, 2016. e-Pub 2016. PMID: 26508094.
      82. Wu AJ, Vapiwala N, Chmura SJ, Das P, Decker RH, Terezakis SA, Zietman AL. Taking "the Game" Out of The Match: A Simple Proposal. Int J Radiat Oncol Biol Phys 93(5):945-8, 2015. e-Pub 2015. PMID: 26581129.
      83. Ye JC, Mohindra P, Spektor A, Krishnan MS, Chmura SJ, Howard AR, Viswanathan AN, MacDonald SM, Thaker NG, Das P, Mancini BR, Higgins SA, Braunstein S, Haas-Kogan D, Bradley KA, Hung AY, Thomas CR Jr, Kharofa J, Wheatley M, Currey A, Parashar B, Du K, Jimenez RB, Golden DW. Medical Student Perspectives on a Multi-institutional Clerkship Curriculum: A Report From the Radiation Oncology Education Collaborative Study Group. Int J Radiat Oncol Biol Phys 92(2):217-9, 2015. e-Pub 2015. PMID: 25968822.
      84. LeMieux MH, Solanki AA, Mahmood U, Chmura SJ, Koshy M. Risk of second malignancies in patients with early-stage classical Hodgkin's lymphoma treated in a modern era. Cancer Med 4(4):513-8, 2015. e-Pub 2015. PMID: 25620577.
      85. Feng CH, Gerry E, Chmura SJ, Hasan Y, Al-Hallaq HA. An image-guided study of setup reproducibility of postmastectomy breast cancer patients treated with inverse-planned intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 91(1):58-64, 2015. e-Pub 2015. PMID: 25442344.
      86. Padilla L, Kang H, Washington M, Hasan Y, Chmura SJ, Al-Hallaq H. Assessment of interfractional variation of the breast surface following conventional patient positioning for whole-breast radiotherapy. J Appl Clin Med Phys 15(5):4921, 2014. e-Pub 2014. PMID: 25207578.
      87. Corbin KS, Dorn PL, Jain SK, Al-Hallaq HA, Hasan Y, Chmura SJ. Hypofractionated radiotherapy does not increase acute toxicity in large-breasted women: results from a prospectively collected series. Am J Clin Oncol 37(4):322-6, 2014. e-Pub 2014. PMID: 23357972.
      88. Tye K, Engelhard HH, Slavin KV, Nicholas MK, Chmura SJ, Kwok Y, Ho DS, Weichselbaum RR, Koshy M. An analysis of radiation necrosis of the central nervous system treated with bevacizumab. J Neurooncol 117(2):321-7, 2014. e-Pub 2014. PMID: 24504500.
      89. Rudra S, Al-Hallaq HA, Feng C, Chmura SJ, Hasan Y. Effect of RTOG breast/chest wall guidelines on dose-volume histogram parameters. J Appl Clin Med Phys 15(2):4547, 2014. e-Pub 2014. PMID: 24710440.
      90. Golden DW, Spektor A, Rudra S, Ranck MC, Krishnan MS, Jimenez RB, Viswanathan AN, Koshy M, Howard AR, Chmura SJ. Radiation oncology medical student clerkship: implementation and evaluation of a bi-institutional pilot curriculum. Int J Radiat Oncol Biol Phys 88(1):45-50, 2014. e-Pub 2014. PMID: 24331650.
      91. Jagadeesan VS, Raleigh DR, Koshy M, Howard AR, Chmura SJ, Golden DW. A national radiation oncology medical student clerkship survey: didactic curricular components increase confidence in clinical competency. Int J Radiat Oncol Biol Phys 88(1):51-6, 2014. e-Pub 2014. PMID: 24331651.
      92. Corbin KS, Ranck MC, Hasselle MD, Golden DW, Partouche J, Wu T, Chmura SJ, Weichselbaum RR, Salama JK. Feasibility and toxicity of hypofractionated image guided radiation therapy for large volume limited metastatic disease. Pract Radiat Oncol 3(4):316-22, 2013. e-Pub 2013. PMID: 24674404.
      93. Liang H, Deng L, Chmura S, Burnette B, Liadis N, Darga T, Beckett MA, Lingen MW, Witt M, Weichselbaum RR, Fu YX. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol 190(11):5874-81, 2013. e-Pub 2013. PMID: 23630355.
      94. Dorn PL, Al-Hallaq HA, Haq F, Goldberg M, Abe H, Hasan Y, Chmura SJ. A prospective study of the utility of magnetic resonance imaging in determining candidacy for partial breast irradiation. Int J Radiat Oncol Biol Phys 85(3):615-22, 2013. e-Pub 2013. PMID: 22836047.
      95. Sekine ES, Toledo VA, Caxambu MG, Chmura S, Takashiba EH, Sereia MJ, Marchini LC, Moreti AC. Melliferous flora and pollen characterization of honey samples of Apis mellifera L., 1758 in apiaries in the counties of Ubirata and Nova Aurora, PR. An Acad Bras Cienc 85(1):307-26, 2013. e-Pub 2013. PMID: 23460431.
      96. Golden DW, Raleigh DR, Chmura SJ, Koshy M, Howard AR. Radiation oncology fourth-year medical student clerkships: a targeted needs assessment. Int J Radiat Oncol Biol Phys 85(2):296-7, 2013. e-Pub 2013. PMID: 22713834.
      97. Solanki AA, Weichselbaum RR, Appelbaum D, Farrey K, Yenice KM, Chmura SJ, Salama JK. The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol 7:216, 2012. e-Pub 2012. PMID: 23244066.
      98. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 118(11):2962-70, 2012. e-Pub 2012. PMID: 22020702.
      99. Dorn PL, Corbin KS, Al-Hallaq H, Hasan Y, Chmura SJ. Feasibility and acute toxicity of hypofractionated radiation in large-breasted patients. Int J Radiat Oncol Biol Phys 83(1):79-83, 2012. e-Pub 2012. PMID: 22035661.
      100. Shakur SF, Takagi I, Lukas RV, Chmura S, Gajewski TF, Roitberg BZ. Ocular melanoma metastasis to the cervical spine. J Clin Neurosci 19(4):610-1, 2012. e-Pub 2012. PMID: 22245271.
      101. Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, Weichselbaum RR, McCarthy BJ. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107(1):207-12, 2012. e-Pub 2012. PMID: 21984115.
      102. Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, Shah N, Hoffman PC, Chmura SJ, Connell PP, Vokes EE, Weichselbaum RR, Salama JK. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol 7(2):376-81, 2012. e-Pub 2012. PMID: 22198429.
      103. Wang X, Liu L, Fackenthal J, Chang P, Newstead G, Chmura S, Foster I, Olopade OI. Towards an Oncology Database (ONCOD) Using a Warehousing Approach. AMIA Jt Summits Transl Sci Proc 2012:105, 2012. e-Pub 2012. PMID: 22779060.
      104. Lussier YA, Khodarev NN, Regan K, Corbin K, Li H, Ganai S, Khan SA, Gnerlich JL, Darga TE, Fan H, Karpenko O, Paty PB, Posner MC, Chmura SJ, Hellman S, Ferguson MK, Weichselbaum RR. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One 7(12):e50141, 2012. e-Pub 2012. PMID: 23251360.
      105. Soria C, Escolano S, El Sabbagh S, Chmura S, Bulteau C, Chiron C, Dellatolas G. Behavioral problems, cognitive difficulties and quality of life in children with epilepsy: an analysis of parental concerns. Child Neuropsychol 18(3):209-27, 2012. e-Pub 2012. PMID: 21942695.
      106. Nichols MA, Mell LK, Hasselle MD, Karrison TG, MacDermed D, Meriwether A, Witt ME, Weichselbaum RR, Chmura SJ. Outcomes in black patients with early breast cancer treated with breast conservation therapy. Int J Radiat Oncol Biol Phys 79(2):392-9, 2011. e-Pub 2011. PMID: 20434849.
      107. Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, Khan SA, Yang X, Hasselle MD, Darga TE, Malik R, Fan H, Perakis S, Filippo M, Corbin K, Lee Y, Posner MC, Chmura SJ, Hellman S, Weichselbaum RR. MicroRNA expression characterizes oligometastasis(es). PLoS One 6(12):e28650, 2011. e-Pub 2011. PMID: 22174856.
      108. Mell LK, Jeong JH, Nichols MA, Polite BN, Weichselbaum RR, Chmura SJ. Predictors of competing mortality in early breast cancer. Cancer 116(23):5365-73, 2010. e-Pub 2010. PMID: 20737562.
      109. Aydogan B, Li J, Rajh T, Chaudhary A, Chmura SJ, Pelizzari C, Wietholt C, Kurtoglu M, Redmond P. AuNP-DG: deoxyglucose-labeled gold nanoparticles as X-ray computed tomography contrast agents for cancer imaging. Mol Imaging Biol 12(5):463-7, 2010. e-Pub 2010. PMID: 20237857.
      110. Li J, Chaudhary A, Chmura SJ, Pelizzari C, Rajh T, Wietholt C, Kurtoglu M, Aydogan B. A novel functional CT contrast agent for molecular imaging of cancer. Phys Med Biol 55(15):4389-97, 2010. e-Pub 2010. PMID: 20647599.
      111. Rizvi SA, Liu S, Chen Z, Skau C, Pytynia M, Kovar DR, Chmura SJ, Kozmin SA. Rationally simplified bistramide analog reversibly targets actin polymerization and inhibits cancer progression in vitro and in vivo. J Am Chem Soc 132(21):7288-90, 2010. e-Pub 2010. PMID: 20455580.
      112. Klinger M, Chmura SA, Killeen N. Reporter alleles that inform on differences in Cre recombinase expression. J Immunol 184(11):6170-6, 2010. e-Pub 2010. PMID: 20427774.
      113. Mortier E, Advincula R, Kim L, Chmura S, Barrera J, Reizis B, Malynn BA, Ma A. Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets. Immunity 31(5):811-22, 2009. e-Pub 2009. PMID: 19913445.
      114. Altman MB, Stinauer MA, Javier D, Smith BD, Herman LC, Pytynia ML, Aydogan B, Pelizzari CA, Chmura SJ, Roeske JC. Validation of temporal optimization effects for a single fraction of radiation in vitro. Int J Radiat Oncol Biol Phys 75(4):1240-6, 2009. e-Pub 2009. PMID: 19857787.
      115. Leunen D, Caroff X, Chmura S, Fohlen M, Delalande O, Jambaque I. Verbal and spatial learning after temporal lobe excisions in children: an adaptation of the Grober and Buschke procedure. Epilepsy Behav 16(3):534-8, 2009. e-Pub 2009. PMID: 19837004.
      116. Devisetty K, Mell LK, Salama JK, Schomas DA, Miller RC, Jani AB, Roeske JC, Aydogan B, Chmura SJ. A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. Radiother Oncol 93(2):298-301, 2009. e-Pub 2009. PMID: 19717198.
      117. Klinger M, Kim JK, Chmura SA, Barczak A, Erle DJ, Killeen N. Thymic OX40 expression discriminates cells undergoing strong responses to selection ligands. J Immunol 182(8):4581-9, 2009. e-Pub 2009. PMID: 19342632.
      118. Altman MB, Vesper BJ, Smith BD, Stinauer MA, Pelizzari CA, Aydogan B, Reft CS, Radosevich JA, Chmura SJ, Roeske JC. Characterization of a novel phantom for three-dimensional in vitro cell experiments. Phys Med Biol 54(5):N75-82, 2009. e-Pub 2009. PMID: 19182327.
      119. Cao J, Roeske JC, Chmura SJ, Salama JK, Shoushtari AN, Boyer AL, Martel MK. Calculation and prediction of the effect of respiratory motion on whole breast radiation therapy dose distributions. Med Dosim 34(2):126-32, 2009. e-Pub 2009. PMID: 19410141.
      120. Al-Hallaq HA, Mell LK, Bradley JA, Chen LF, Ali AN, Weichselbaum RR, Newstead GM, Chmura SJ. Magnetic resonance imaging identifies multifocal and multicentric disease in breast cancer patients who are eligible for partial breast irradiation. Cancer 113(9):2408-14, 2008. e-Pub 2008. PMID: 18823018.
      121. Salama JK, Chmura SJ, Mehta N, Yenice KM, Stadler WM, Vokes EE, Haraf DJ, Hellman S, Weichselbaum RR. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res 14(16):5255-9, 2008. e-Pub 2008. PMID: 18698045.
      122. Mell LK, Schomas DA, Salama JK, Devisetty K, Aydogan B, Miller RC, Jani AB, Kindler HL, Mundt AJ, Roeske JC, Chmura SJ. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 70(5):1431-7, 2008. e-Pub 2008. PMID: 17996390.
      123. Salama JK, Mell LK, Schomas DA, Miller RC, Devisetty K, Jani AB, Mundt AJ, Roeske JC, Liauw SL, Chmura SJ. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 25(29):4581-6, 2007. e-Pub 2007. PMID: 17925552.
      124. Altman MB, Chmura SJ, Deasy JO, Roeske JC. Optimization of the temporal pattern of radiation: an IMRT based study. Int J Radiat Oncol Biol Phys 66(3):898-905, 2006. e-Pub 2006. PMID: 17011463.
      125. Kochanski JD, Chmura SJ. Is postmastectomy radiotherapy useful in elderly women with high-risk breast cancer?. Nat Clin Pract Oncol 3(8):422-3, 2006. e-Pub 2006. PMID: 16894385.
      126. Milano MT, Garofalo MC, Chmura SJ, Farrey K, Rash C, Heimann R, Jani AB. Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. Br J Radiol 79(942):497-503, 2006. e-Pub 2006. PMID: 16714752.
      127. Milano MT, Vokes EE, Kao J, Jackson W, List MA, Stenson KM, Witt ME, Dekker A, MacCracken E, Garofalo MC, Chmura SJ, Weichselbaum RR, Haraf DJ. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol 28(5):1141-51, 2006. e-Pub 2006. PMID: 16596230.
      128. Salama JK, Vokes EE, Chmura SJ, Milano MT, Kao J, Stenson KM, Witt ME, Haraf DJ. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 64(2):382-91, 2006. e-Pub 2006. PMID: 16213104.
      129. Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 63(2):354-61, 2005. e-Pub 2005. PMID: 16168830.
      130. Salama JK, Heimann R, Lin F, Mehta N, Chmura SJ, Singh R, Kao J. Does the number of lymph nodes examined in patients with lymph node-negative breast carcinoma have prognostic significance?. Cancer 103(4):664-71, 2005. e-Pub 2005. PMID: 15641038.
      131. Milano MT, Chmura SJ, Garofalo MC, Rash C, Roeske JC, Connell PP, Kwon OH, Jani AB, Heimann R. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 59(2):445-53, 2004. e-Pub 2004. PMID: 15145161.
      132. Jacobelli J, Chmura SA, Buxton DB, Davis MM, Krummel MF. A single class II myosin modulates T cell motility and stopping, but not synapse formation. Nat Immunol 5(5):531-8, 2004. e-Pub 2004. PMID: 15064761.
      133. Chave KJ, Ryan TJ, Chmura SE, Galivan J. Identification of single nucleotide polymorphisms in the human gamma-glutamyl hydrolase gene and characterization of promoter polymorphisms. Gene 319:167-75, 2003. e-Pub 2003. PMID: 14597182.
      134. Chmura SJ, Nodzenski E, Kharbanda S, Pandey P, Quintans J, Kufe DW, Weichselbaum RR. Down-regulation of ceramide production abrogates ionizing radiation-induced cytochrome c release and apoptosis. Mol Pharmacol 57(4):792-6, 2000. e-Pub 2000. PMID: 10727527.
      135. Chmura SJ, Dolan ME, Cha A, Mauceri HJ, Kufe DW, Weichselbaum RR. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clin Cancer Res 6(2):737-42, 2000. e-Pub 2000. PMID: 10690561.
      136. Beck TP, Kirsh EJ, Chmura SJ, Kovar DA, Chung T, Rinker-Schaeffer CW, Stadler WM. In vitro evaluation of calphostin C as a novel agent for photodynamic therapy of bladder cancer. Urology 54(3):573-7, 1999. e-Pub 1999. PMID: 10475376.
      137. Dubauskas Z, Beck TP, Chmura SJ, Kovar DA, Kadkhodaian MM, Shrivastav M, Chung T, Stadler WM, Rinker-Schaeffer CW. Activated calphostin C cytotoxicity is independent of p53 status and in vivo metastatic potential. Clin Cancer Res 4(10):2391-8, 1998. e-Pub 1998. PMID: 9796970.
      138. Chmura SJ, Mauceri HJ, Advani S, Heimann R, Beckett MA, Nodzenski E, Quintans J, Kufe DW, Weichselbaum RR. Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. Cancer Res 57(19):4340-7, 1997. e-Pub 1997. PMID: 9331096.
      139. Chmura SJ, Nodzenski E, Beckett MA, Kufe DW, Quintans J, Weichselbaum RR. Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res 57(7):1270-5, 1997. e-Pub 1997. PMID: 9102212.
      140. Chmura SJ, Nodzenski E, Weichselbaum RR, Quintans J. Protein kinase C inhibition induces apoptosis and ceramide production through activation of a neutral sphingomyelinase. Cancer Res 56(12):2711-4, 1996. e-Pub 1996. PMID: 8665499.
      141. Chmura SJ, Nodzenski E, Crane MA, Virudachalam S, Hallahan DE, Weichselbaum RR, Quintans J. Cross-talk between ceramide and PKC activity in the control of apoptosis in WEHI-231. Adv Exp Med Biol 406:39-55, 1996. e-Pub 1996. PMID: 8910670.
      142. Westbrook CA, Chmura SJ, Arenas RB, Kim SY, Otto G. Human APC gene expression in rodent colonic epithelium in vivo using liposomal gene delivery. Hum Mol Genet 3(11):2005-10, 1994. e-Pub 1994. PMID: 7874118.
      143. Chmura S. Hamartoma trzustki. Pol Przegl Chir 49(11):1169-70, 1977. e-Pub 1977. PMID: 304575.
      144. Chmura S, Sztajerwald-Hola C. Uszkodzenie pecherzyka zolciowego w wyniku tepego urazu brzucha. Pol Przegl Chir 48(3):413-4, 1976. e-Pub 1976. PMID: 1264877.

      Review Articles

      1. Soliman S, Zitter R, Walker S, Chmura S, Eniu A, Graff SL. Evolving Treatment Paradigms in Hormone Receptor-Positive, Human Epidermal Growth Factor 2-Negative Metastatic Breast Cancer. Am Soc Clin Oncol Educ Book 46(3):e520518, 2026. e-Pub 2026. PMID: 42155073.
      2. Katipally RR, Pitroda SP, Juloori A, Chmura SJ, Weichselbaum RR. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol 19(9):585-599, 2022. e-Pub 2022. PMID: 35831494.
      3. Strauss JB, Chmura SJ. Oligometastatic Breast Cancer. Semin Radiat Oncol 32(3):282-290, 2022. e-Pub 2022. PMID: 35688526.
      4. Turchan WT, Chmura SJ. The role of immunotherapy in combination with oligometastasis-directed therapy: a narrative review. Ann Palliat Med 10(5):6028-6044, 2021. e-Pub 2021. PMID: 33440982.
      5. Onderdonk BE, Gutiontov SI, Chmura SJ. The Evolution (and Future) of Stereotactic Body Radiotherapy in the Treatment of Oligometastatic Disease. Hematol Oncol Clin North Am 34(1):307-320, 2020. e-Pub 2020. PMID: 31739951.
      6. Pitroda SP, Chmura SJ, Weichselbaum RR. Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol 20(8):e434-e442, 2019. e-Pub 2019. PMID: 31364595.
      7. Page DB, Bear H, Prabhakaran S, Gatti-Mays ME, Thomas A, Cobain E, McArthur H, Balko JM, Gameiro SR, Nanda R, Gulley JL, Kalinsky K, White J, Litton J, Chmura SJ, Polley MY, Vincent B, Cescon DW, Disis ML, Sparano JA, Mittendorf EA, Adams S. Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. NPJ Breast Cancer 5:34, 2019. e-Pub 2019. PMID: 31602395.
      8. Onderdonk BE, Chmura SJ. The Yin and Yang of Cytoreductive SBRT in Oligometastases and Beyond. Front Oncol 9:706, 2019. e-Pub 2019. PMID: 31428580.
      9. Mayo CS, Moran JM, Bosch W, Xiao Y, McNutt T, Popple R, Michalski J, Feng M, Marks LB, Fuller CD, Yorke E, Palta J, Gabriel PE, Molineu A, Matuszak MM, Covington E, Masi K, Richardson SL, Ritter T, Morgas T, Flampouri S, Santanam L, Moore JA, Purdie TG, Miller RC, Hurkmans C, Adams J, Jackie Wu QR, Fox CJ, Siochi RA, Brown NL, Verbakel W, Archambault Y, Chmura SJ, Dekker AL, Eagle DG, Fitzgerald TJ, Hong T, Kapoor R, Lansing B, Jolly S, Napolitano ME, Percy J, Rose MS, Siddiqui S, Schadt C, Simon WE, Straube WL, St James ST, Ulin K, Yom SS, Yock TI. American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology. Int J Radiat Oncol Biol Phys 100(4):1057-1066, 2018. e-Pub 2018. PMID: 29485047.
      10. Jutzy JMS, Lemons JM, Luke JJ, Chmura SJ. The Evolution of Radiation Therapy in Metastatic Breast Cancer: From Local Therapy to Systemic Agent. Int J Breast Cancer 2018:4786819, 2018. e-Pub 2018. PMID: 29862083.
      11. Young JS, Chmura SJ, Wainwright DA, Yamini B, Peters KB, Lukas RV. Management of glioblastoma in elderly patients. J Neurol Sci 380:250-255, 2017. e-Pub 2017. PMID: 28870580.
      12. Bergsma DP, Salama JK, Singh DP, Chmura SJ, Milano MT. Radiotherapy for Oligometastatic Lung Cancer. Front Oncol 7:210, 2017. e-Pub 2017. PMID: 28975081.
      13. Drazer MW, Salama JK, Hahn OM, Weichselbaum RR, Chmura SJ. Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting?. Expert Rev Anticancer Ther 16(6):625-32, 2016. e-Pub 2016. PMID: 27078719.
      14. Bergsma DP, Salama JK, Singh DP, Chmura SJ, Milano MT. The evolving role of radiotherapy in treatment of oligometastatic NSCLC. Expert Rev Anticancer Ther 15(12):1459-71, 2015. e-Pub 2015. PMID: 26536370.
      15. Salama JK, Chmura SJ. Surgery or ablative radiotherapy for breast cancer oligometastases. Am Soc Clin Oncol Educ Book:e8-15, 2015. e-Pub 2015. PMID: 25993242.
      16. Salama JK, Chmura SJ. The role of surgery and ablative radiotherapy in oligometastatic breast cancer. Semin Oncol 41(6):790-7, 2014. e-Pub 2014. PMID: 25499637.
      17. Lukas RV, Gabikian P, Garza M, Chmura SJ. Treatment of brain metastases. Oncology 87(6):321-9, 2014. e-Pub 2014. PMID: 25227433.
      18. Chmura SJ, Salama JK, Weichselbaum RR. Stereotactic radiotherapy for pulmonary metastases. Semin Thorac Cardiovasc Surg 25(4):292-9, 2013. e-Pub 2013. PMID: 24673958.
      19. Nicholas MK, Lukas RV, Chmura S, Yamini B, Lesniak M, Pytel P. Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Semin Oncol 38(2):243-53, 2011. e-Pub 2011. PMID: 21421114.
      20. Advani SJ, Weichselbaum RR, Chmura SJ. Enhancing radiotherapy with genetically engineered viruses. J Clin Oncol 25(26):4090-5, 2007. e-Pub 2007. PMID: 17827458.
      21. Devisetty K, Chen LF, Chmura SJ. Evolving use of radiotherapy and radiosurgery in the treatment of pituitary adenomas. Expert Rev Anticancer Ther 6 Suppl 9:S93-8, 2006. e-Pub 2006. PMID: 17004863.
      22. Kao J, Milano MT, Javaheri A, Garofalo MC, Chmura SJ, Weichselbaum RR, Kron SJ. gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets 6(3):197-205, 2006. e-Pub 2006. PMID: 16712457.
      23. Chmura SJ, Milano MT, Haraf DJ. Reirradiation of recurrent head and neck cancers with curative intent. Semin Oncol 31(6):816-21, 2004. e-Pub 2004. PMID: 15599860.
      24. Kao J, Garofalo MC, Milano MT, Chmura SJ, Citron JR, Haraf DJ. Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review. Cancer Treat Rev 29(1):21-30, 2003. e-Pub 2003. PMID: 12633577.
      25. Chmura SJ, Gupta N, Advani SJ, Kufe DW, Weichselbaum RR. Prospects for viral-based strategies enhancing the anti-tumor effects of ionizing radiation. Semin Radiat Oncol 11(4):338-45, 2001. e-Pub 2001. PMID: 11677658.
      26. Chmura SJ, Advani SJ, Kufe DW, Weichselbaum RR. Strategies for enhancing viral-based gene therapy using ionizing radiation. Radiat Oncol Investig 7(5):261-9, 1999. e-Pub 1999. PMID: 10580895.
      27. Advani SJ, Chmura SJ, Weichselbaum RR. Radiogenetic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumors. Semin Oncol 24(6):633-8, 1997. e-Pub 1997. PMID: 9422260.

      Other Articles

      1. Piffko A, Yang K, Panda A, Heide J, Tesak K, Wen C, Zawieracz K, Wang L, Naccasha EZ, Bugno J, Fu Y, Chen D, Donle L, Lengyel E, Tilley DG, Mack M, Rock RS, Chmura SJ, Vokes EE, He C, Pitroda SP, Liang HL, Weichselbaum RR Publisher Correction: Radiation-induced amphiregulin drives tumour metastasis. Nature 647(8091):E9, 2025. PMID: 41214352.
      2. Yang K, Hou Y, Zhang Y, Liang H, Sharma A, Zheng W, Wang L, Torres R, Tatebe K, Chmura SJ, Pitroda SP, Gilbert JA, Fu YX, Weichselbaum RR Correction: Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J Exp Med 222(10), 2025. PMID: 40970935.
      3. Pusztai L, Rozenblit M, Dubsky P, Bachelot T, Kirby AM, Linderholm BK, White JR, Chmura SJ, Carey LA, Chua BH, Miller KD Erratum: De Novo Oligometastatic Breast Cancer. J Clin Oncol 43(24):2758, 2025. PMID: 40690726.

      Editorials

      1. Katipally RR, Olson AC, Chmura SJ. Flipping the Null: Lessons From Breast Cancer and Recalibrating Expectations in Oligometastases. Int J Radiat Oncol Biol Phys 114(5):840-842, 2022. PMID: 36395805.
      2. Glicksman RM, Palma DA, Deek MP, Tsai CJ, Chmura S, Siva S, Ost P, Tran PT, Berlin A. Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It?. Int J Radiat Oncol Biol Phys 114(4):561-570, 2022. PMID: 36244387.
      3. Tran PT, Sutera P, Phillips RM, Deek MP, Chmura S. From Idea to Clinical Practice: A Brief History of Oligometastatic Disease. Int J Radiat Oncol Biol Phys 114(4):576-580, 2022. PMID: 36244393.
      4. Milano MT, Chmura SJ. Cautioning Against Declaring Success Before the Finish Line. Int J Radiat Oncol Biol Phys 112(2):376-378, 2022. PMID: 34998534.
      5. Gutiontov SI, Pitroda SP, Chmura SJ, Arina A, Weichselbaum RR. Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. Int J Radiat Oncol Biol Phys 108(1):17-26, 2020. PMID: 32819613.
      6. Milano MT, Chowdhry AK, Salama JK, Chmura SJ. Signals from SABR-COMET time to move on to phase III studies. Ann Transl Med 7(Suppl 8):S316, 2019. PMID: 32016034.

      Abstracts

      1. Chmura S, Matlak J. Naczyniak limfatyczny krezki przyczyna niedroznosci mechanicznej jelit. Pol Przegl Chir 47(9A):81-2, 1975. e-Pub 1975. PMID: 1187485.
      2. Chmura S. Masywny krowotok z tetnicy pecherzykowej do jamy otrzewnej jako powiklanie kamicy zolciowej. Pol Przegl Chir 46(4):553-4, 1974. e-Pub 1974. PMID: 4839837.

      Letters to the Editor

      1. Chmura SJ, Woodward WA, White JR. Reply to J. Widder. J Clin Oncol 41: 939-940, 2023.
      2. Foster CC, Chmura SJ. Putting the "BR" in SBRT. Int J Radiat Oncol Biol Phys 102: 13-14, 2018.
      3. Luke JJ, Chmura SJ. Reply to S.C. Formenti et al. J Clin Oncol 36: 2662-2663, 2018.
      Read More
      Less

      Patient Reviews


      CV information above last modified November 02, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top